



# ERS course on Eosinophilic Lung Diseases

## 13-14 March 2026

### London, United Kingdom

---

#### Friday, 13 March 2026

---

08:30–09:00	Welcome and registration
	<b>Session 1 - An introduction to the eosinophil</b>
09:00–09:10	Welcome & introduction - D. Jackson
09:10–09:40	The eosinophil: A historic perspective - F. Roufosse
09:40–10:10	Interactions between eosinophils and type 2 innate lymphoid cells – C. Klose
10:10–10:40	Interactions between eosinophils and other lymphocyte subsets - A. Munitz
10:40–11:10	Eosinophil extracellular traps – S. Ueki
11:10–11:30	<i>Break</i>
	<b>Session 2 - Eosinophils and airway exacerbations</b>
11:30–12:00	Eosinophils and respiratory virus infection - H. Rupani
12:00–12:30	Eosinophils and airway nerve activity - M. Drake
12:30–13:00	Understanding exacerbations on anti-IL5/5R biologics - L. Heaney
13:00–14:00	<i>Lunch break</i>
	<b>Session 3 - Insights from using anti-T2 biologics</b>
14:00–14:30	How sufficient is TSLP as a target in eosinophilic asthma? - M. Wechsler
14:30–15:00	How sufficient is IL-5/5R as a target in EGPA? - A. Nanzer
15:00–15:30	IL5/5R vs IL-4R as a target in eosinophilic COPD - M. Bafadhel
15:30–16:00	How dangerous is depleting eosinophils? - D. Jackson
16:00–16:15	<i>Break</i>



#### **Session 4 - Clinical approach and management of eosinophilic lung diseases: Part 1**

16:15–16:45	The differential diagnosis of pulmonary eosinophilia - B. Kent
16:45–17:15	Hypereosinophilic syndromes with pulmonary involvement – F. Roufosse
17:15–17:45	Chronic eosinophilic pneumonia - J. Dhariwal

---

## **Saturday, 14 March 2026**

---

#### **Session 5 - Clinical approach and management of eosinophilic lung diseases: Part 2**

09:00–09:30	Eosinophilic bronchiectasis - J. Chalmers
09:30–10:00	ABPA and fungus-driven eosinophilic inflammation – S. Ueki
10:00–10:30	Chronic rhinosinusitis and nasal polyposis - C. Hopkins

10:30–10:50 *Break*

#### **Session 6 - Research techniques in eosinophilic diseases**

10:50–11:20	Overview of techniques for studying the eosinophil - C. Desmet
11:20–11:50	Single-cell transcriptomic profiling - I. Arnold
11:50–12:20	Mouse models of eosinophil associated diseases - A. Munitz
12:20–12:50	Assessing eosinophil activation in human disease - TBC
12:50–13:00	Closing remarks - D. Jackson